Editor’s Note November 22, 2011

OneMedForum SF 2012 is around the corner and we are gearing up to present some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue:

DATATRAK [DATA.PK] expands into Chinese Market. Announces third quarter results.

Peter Winter, consultant to the biotechnology industry, brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.

Neovasc [TSXV:NVC] refractory Angina treatment receives CE Mark.

Wound Management Technologies, [WNDM.PK]  today announced that its subsidiary, Resorbable Orthopedic Products, LLC, has entered into a Development and License Agreement with Newport Beach, CA-based BioStructures, LLC to develop products for bone remodeling in the human skeletal system based on ROP’s patent.  BioStructures has paid ROP an initial $100K licensing fee and the agreement calls for ROP to receive additional license fees as well as royalties on sales throughout the life of the patent.

IntelGenx‘s anti-depressant received FDA approval.

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices, announced that the first patient has received the FDA-approved Implantable Miniature Telescope procedure indicated to improve vision in patients with end-stage age-related macular degeneration (AMD).

The comments are closed.